Veligrotug Shows Promise for Treating Thyroid Eye Disease

The THRIVE and THRIVE-2 clinical trials showed significant improvements in proptosis and diplopia in active as well as chronic thyroid eye disease, earning FDA Breakthrough Therapy designation.
Medscape Medical News